Biotech outperformance expected to continue in 2026, Baird analysts sayProactive Investors • 01/09/26
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a BetZacks Investment Research • 11/20/25
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/25
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 11/04/25
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to TradeZacks Investment Research • 10/30/25
Ocular Therapeutix (OCUL) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 10/24/25
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common StockGlobeNewsWire • 09/30/25
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary EndpointGlobeNewsWire • 09/30/25
Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/25
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused CompanyGlobeNewsWire • 06/26/25
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?Zacks Investment Research • 06/25/25
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025GlobeNewsWire • 06/16/25
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge UpsideBenzinga • 03/11/25